Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
99mTc-C02 is a technetium-99m (99mTc) radiolabeled derivative of the CXCR4 antagonist AMD070 (mavorixafor). It was developed by researchers at The First Affiliated Hospital of Chongqing Medical University as a novel molecular probe for single-photon emission computed tomography (SPECT) imaging of C-X-C chemokine receptor type 4 (CXCR4) expression. In preclinical evaluations, 99mTc-C02 demonstrated high and specific uptake in CXCR4-expressing cells, including Jurkat T-cell lymphoma and 4T1 breast cancer cells, as well as favorable tumor-to-background ratios in 4T1 xenograft-bearing mice. It represents a potential SPECT-based alternative to PET-based CXCR4 imaging agents like 68Ga-Pentixafor.
| Indication | Highest phase | Status |
|---|---|---|
| breast cancer and precursor lesions | Preclinical | Active |
| hematologic lymphomas | Preclinical | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Lead indication: breast cancer and precursor lesions
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 99mTc-C02.
Work on 99mTc-C02? Claim this page to correct or add information. Claim this page